The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus for Korean patients with metastatic renal cell carcinoma who have failed initial treatment of a vascular endothelial growth factor (VEGF): Tyrosine kinase inhibitor (TKI).
Kwonoh Park
No relevant relationships to disclose
Jin-Hee Ahn
No relevant relationships to disclose
Cheryn Song
No relevant relationships to disclose
Jun Hyuk Hong
No relevant relationships to disclose
Choung-Soo Kim
No relevant relationships to disclose
Hanjong Ahn
No relevant relationships to disclose
Jae-Lyun Lee
No relevant relationships to disclose